Classifications: antibiotic; second-generation cephalosporin; Therapeutic: antibiotic; cephalosporin
Pregnancy Category: B
250 mg, 500 mg tablets; 125 mg/5 mL, 250 mg/5 mL suspension
Semisynthetic, second-generation cephalosporin antibiotic with drug structure characterized by a beta-lactam ring; generally
resistant to hydrolysis by beta-lactamases. Preferentially binds to proteins in cell walls of susceptible organisms, thus
killing the bacteria.
Third-generation cephalosporins are more active and have a broader spectrum against gram-negative bacteria than first- or
second-generation of cephalosporins.
Upper and lower respiratory tract infections, otitis media, skin infections.
Hypersensitivity to cephalosporin and related antibiotics; severely impaired renal or hepatic function; phenylketonuria
(PKU); infants <6 mo.
Patients with delayed reaction to penicillin or other drugs; coagulopathy; renal impairment, renal disease; GI disease,
especially colitis; pregnancy (category B).
Route & Dosage
|Mild to Moderate Infections
Adult: PO 250500 mg q1224h for 1014 d
Child (>6 mo): PO 15 mg/kg q12h
- Drug may be given without regard to meals.
- Consult physician for patients with impaired renal function. Dose is reduced by 50% when creatinine clearance is 030
- Administer after hemodialysis since drug is partially removed by dialysis.
- After reconstitution, oral suspension is refrigerated. Discard unused portion after 14 d.
Adverse Effects (≥1%) Body as a Whole:
Hypersensitivity reactions, superinfections. GI:
Nausea, vomiting, diarrhea
, abdominal pain. Hematologic:
Rash, diaper rash. Urogenital:
Genital pruritus, vaginal candidiasis
Diagnostic Test Interference
May cause a positive direct Coombs' test; false-negative results in the ferricyanide assay for blood glucose; false-positive reactions for urine glucose with copper reduction tests such as Benedict's or Fehling's solution or Clinitest tablets; increased partial thromboplastin time, indicating thrombocytosis, eosinophilia; minor elevations in serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and bilirubin.
prolongs the elimination of cefprozil.
Readily from GI tract. Peak:
12 h. Distribution:
Distributes into blister fluid at 50% of the serum
Primarily by kidneys. Half-Life:
Assessment & Drug Effects
- Determine previous hypersensitivity to cephalosporins or penicillins before treatment.
- Withhold drug and notify physician if hypersensitivity occurs (e.g., rash, urticaria).
- Lab tests: Perform culture and sensitivity tests before and periodically during therapy. Therapy may be initiated while
results are pending.
- Monitor for and report diarrhea, as pseudomembranous colitis is a potential adverse effect.
- Monitor for and report signs of superinfection (see Appendix F).
- When given concurrently with other cephalosporins or aminoglycosides, monitor for signs of nephrotoxicity.
Patient & Family Education
- Complete the prescribed course of therapy, even if symptom free.
- Report rash or other signs of hypersensitivity immediately.
- Report signs of superinfection (see Appendix F).
- Report loose stools and diarrhea even after completion of drug therapy.